191 related articles for article (PubMed ID: 27251585)
1. Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.
Byrum ML; Pondenis HC; Fredrickson RL; Wycislo KL; Fan TM
J Vet Intern Med; 2016 Jul; 30(4):1187-96. PubMed ID: 27251585
[TBL] [Abstract][Full Text] [Related]
2. Investigating CXCR4 expression in canine appendicular osteosarcoma.
Fan TM; Barger AM; Fredrickson RL; Fitzsimmons D; Garrett LD
J Vet Intern Med; 2008; 22(3):602-8. PubMed ID: 18466248
[TBL] [Abstract][Full Text] [Related]
3. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.
Wolfe TD; Pillai SP; Hildreth BE; Lanigan LG; Martin CK; Werbeck JL; Rosol TJ
Clin Exp Metastasis; 2011 Apr; 28(4):377-89. PubMed ID: 21374084
[TBL] [Abstract][Full Text] [Related]
4. The Association of Endothelin-1 Signaling with Bone Alkaline Phosphatase Expression and Protumorigenic Activities in Canine Osteosarcoma.
Neumann ZL; Pondenis HC; Masyr A; Byrum ML; Wycislo KL; Fan TM
J Vet Intern Med; 2015; 29(6):1584-94. PubMed ID: 26426813
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.
Cheng HL; Lin CW; Yang JS; Hsieh MJ; Yang SF; Lu KH
Oncotarget; 2016 Mar; 7(9):9742-58. PubMed ID: 26848867
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study.
Smith AA; Lindley SES; Almond GT; Bergman NS; Matz BM; Smith AN
Vet Med Sci; 2023 Jan; 9(1):59-67. PubMed ID: 36398717
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate-Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma.
Lundberg AP; Roady PJ; Somrak AJ; Howes ME; Fan TM
J Vet Intern Med; 2016 Jul; 30(4):1235-40. PubMed ID: 27296235
[No Abstract] [Full Text] [Related]
8. Pro-tumorigenic effects of transforming growth factor beta 1 in canine osteosarcoma.
Portela RF; Fadl-Alla BA; Pondenis HC; Byrum ML; Garrett LD; Wycislo KL; Borst LB; Fan TM
J Vet Intern Med; 2014; 28(3):894-904. PubMed ID: 24684686
[TBL] [Abstract][Full Text] [Related]
9. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis.
Fan TM; de Lorimier LP; Garrett LD; Lacoste HI
J Vet Intern Med; 2008; 22(2):380-7. PubMed ID: 18346146
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance and in vitro cellular regulation of hypoxia mimicry on HIF-1α and downstream genes in canine appendicular osteosarcoma.
Gola C; Iussich S; Noury S; Martano M; Gattino F; Morello E; Martignani E; Maniscalco L; Accornero P; Buracco P; Aresu L; De Maria R
Vet J; 2020 Oct; 264():105538. PubMed ID: 33012439
[TBL] [Abstract][Full Text] [Related]
11. Effects of transplantation sites on tumour growth, pulmonary metastasis and ezrin expression of canine osteosarcoma cell lines in nude mice.
Jaroensong T; Endo Y; Lee SJ; Kamida A; Mochizuki M; Nishimura R; Sasaki N; Nakagawa T
Vet Comp Oncol; 2012 Dec; 10(4):274-82. PubMed ID: 22236104
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
Moriceau G; Ory B; Mitrofan L; Riganti C; Blanchard F; Brion R; Charrier C; Battaglia S; Pilet P; Denis MG; Shultz LD; Mönkkönen J; Rédini F; Heymann D
Cancer Res; 2010 Dec; 70(24):10329-39. PubMed ID: 20971812
[TBL] [Abstract][Full Text] [Related]
13. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA
BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation.
Avnet S; Di Pompo G; Chano T; Errani C; Ibrahim-Hashim A; Gillies RJ; Donati DM; Baldini N
Int J Cancer; 2017 Mar; 140(6):1331-1345. PubMed ID: 27888521
[TBL] [Abstract][Full Text] [Related]
15. PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells.
Xi Y; Qi Z; Ma J; Chen Y
Clin Exp Metastasis; 2020 Feb; 37(1):173-185. PubMed ID: 31571016
[TBL] [Abstract][Full Text] [Related]
16. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
Liu M; Sun LL; Li YJ; Li HY; Zhang J; Li BH; Ye ZM
Int Immunopharmacol; 2015 Sep; 28(1):160-7. PubMed ID: 26071219
[TBL] [Abstract][Full Text] [Related]
18. Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.
Regan DP; Chow L; Das S; Haines L; Palmer E; Kurihara JN; Coy JW; Mathias A; Thamm DH; Gustafson DL; Dow SW
Clin Cancer Res; 2022 Feb; 28(4):662-676. PubMed ID: 34580111
[TBL] [Abstract][Full Text] [Related]
19. The effects of sulforaphane on canine osteosarcoma proliferation and invasion.
Rizzo VL; Levine CB; Wakshlag JJ
Vet Comp Oncol; 2017 Sep; 15(3):718-730. PubMed ID: 27045198
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors.
Levine RA; Forest T; Smith C
Vet Pathol; 2002 May; 39(3):372-8. PubMed ID: 12014501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
